

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI737724

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	Release of Intellectual Property Security Agreement recorded at R/F 63227/0852	
CONVEYING PARTY DATA		
Name		Execution Date
NEWSTONE CAPITAL PARTNERS, LLC		01/07/2025
RECEIVING PARTY DATA		
Company Name:	TERSERA THERAPEUTICS LLC	
Street Address:	520 LAKE COOK RD, SUITE 500	
City:	DEERFIELD	
State/Country:	ILLINOIS	
Postal Code:	60015	
PROPERTY NUMBERS Total: 34		
Property Type	Number	
Application Number:	15967054	
Application Number:	16688658	
Application Number:	17317120	
Patent Number:	7268109	
Patent Number:	7524812	
Patent Number:	7833973	
Patent Number:	7977307	
Patent Number:	7956030	
Patent Number:	8268774	
Patent Number:	8513198	
Patent Number:	8653033	
Patent Number:	8765680	
Patent Number:	9707270	
Patent Number:	10307463	
Patent Number:	10857204	
Patent Number:	7723345	
Patent Number:	8063057	
Patent Number:	8629156	
Patent Number:	7855291	
Patent Number:	7897763	

PATENT

Property Type	Number
Patent Number:	8450532
Patent Number:	7553840
Patent Number:	7709493
Patent Number:	7968559
Patent Number:	8772482
Patent Number:	8093291
Patent Number:	7875622
Patent Number:	8410121
Patent Number:	8193204
Patent Number:	8653094
Patent Number:	8575362
Patent Number:	7968729
Patent Number:	8772483
Patent Number:	7500964

CORRESPONDENCE DATA

Fax Number: 3128622200

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 3128623135

Email: barbara.siepka@kirkland.com

Correspondent Name: Ms. Barbara M Siepka

Address Line 1: KIRKLAND & ELLIS LLP

Address Line 2: 333 West Wolf Point Plaza

Address Line 4: Chicago, ILLINOIS 60654

ATTORNEY DOCKET NUMBER: 25737-24

NAME OF SUBMITTER: Barbara Siepka

SIGNATURE: Barbara Siepka

DATE SIGNED: 01/07/2025

Total Attachments: 7

source=TerSera - Release of Intellectual Property Security Agreements Executed#page1.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page2.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page3.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page4.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page5.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page6.tiff

source=TerSera - Release of Intellectual Property Security Agreements Executed#page7.tiff

RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS

This **RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENTS**, dated as of January 7, 2025 (this “**Release**”), is made by **NEWSTONE CAPITAL PARTNERS, LLC**, in its capacity as agent for Secured Parties (in such capacity, the “**Agent**”) as defined in the Second Lien Guaranty and Security Agreement referred to below. All capitalized terms used, but not otherwise defined herein, shall have the meanings set forth in the Second Lien Guaranty and Security Agreement or in the Intellectual Property Security Agreements referred to below.

WHEREAS, in connection with that certain Second Lien Guaranty and Security Agreement, dated as of April 4, 2023 (as amended, restated, supplemented or otherwise modified from time to time, the “**Guaranty and Security Agreement**”), by and among the Grantors and the Agent, the Grantors, as collateral security for the Secured Obligations, granted to the Agent a security interest in and continuing lien on all of their right, title and interest in, to and under the Collateral, including without limitation, certain Intellectual Property of the Grantors;

WHEREAS, in connection with the Second Lien Guaranty and Security Agreement and pursuant to those certain agreements described on Annex I attached hereto (collectively, the “**Intellectual Property Security Agreements**”), certain of the Grantors granted to the Agent a security interest in their Intellectual Property as Collateral, including the Patent Collateral and Trademark Collateral (each as defined in the Intellectual Property Security Agreements); and

WHEREAS, certain of the Intellectual Property Security Agreements were recorded in the United States Patent and Trademark Office or the United States Copyright Office, as applicable, on the dates and on the reel and frame numbers set forth on Annex I hereto.

NOW THEREFORE, in consideration of the material covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Agent hereby releases, terminates and discharges, without representation, recourse or warranty whatsoever, all of its rights in, to and under, including its lien on and security interest in, and right of setoff against all such Intellectual Property within Collateral, whether granted pursuant to the Intellectual Property Security Agreements or any other agreement or document delivered in connection with the Pledge and Security Agreement, and the Agent hereby reassigns any and all such right, title and interest (if any) that the Agent may have in, to and under all such Intellectual Property within Collateral to the Grantors.

This Release shall be governed by, and construed and interpreted in accordance with, the laws of the State of New York.

[Signature Page Follows]

IN WITNESS WHEREOF, the Agent has executed this Release as of the date first written above.

NEWSTONE CAPITAL PARTNERS, LLC, as
Agent

By: 

Name: Timothy P. Costello

Title: Managing Director

[SIGNATURE PAGE TO RELEASE OF SECOND LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENTS]

PATENT
REEL: 069835 FRAME: 0707

SCHEDULE 1

INTELLECTUAL PROPERTY SECURITY AGREEMENTS TO BE TERMINATED

1. Second Lien Patent Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of April 4, 2023 and recorded in the United States Patent and Trademark Security Office on April 5, 2023 at Reel/Frame 063227/0852 covering the following:

REGISTERED PATENTS AND PATENT APPLICATIONS

Title / Name	Application No.	Grant No.
METHODS OF MINIMIZING OR PREVENTING DRUG-DRUG INTERACTIONS	15/967054	Pending
METHOD FOR REDUCING PAIN	10/956252	7268109
PHARMACEUTICAL FORMULATION COMPRISING ZICONOTIDE	11/831696	7524812
PHARMACEUTICAL FORMULATIONS FOR REDUCING PAIN	12/483673	7833973
METHOD FOR REDUCING PAIN WITH ZICONOTIDE AND MORPHINE	12/898516	7977307
METHOD FOR REDUCING PAIN WITH ZICONOTIDE AND BACLOFEN	12/898525	7956030
METHOD FOR REDUCING PAIN	13/176568	8268774
PHARMACEUTICAL FORMULATION FOR REDUCING PAIN	13/616607	8513198
METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	13/791715	8653033
METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	14/133303	8765680
METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	14/788524	9707270
METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	15/651655	10307463
METHOD FOR ADMINISTERING OMEGA-CONOPEPTIDE	16/402145	10857204
MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE	11/638677	7723345
MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE	12/750278	8063057
TRYPTOPHAN HYDROXYLASE INHIBITORS	13/290261	8629156
PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYLALANINES	11/647517	7855291
PROCESS FOR THE PREPARATION OF SUBSTITUTED PHENYLALANINES	12/257558	7897763
Compounds useful in the preparation of tryptophan hydroxylase inhibitors	13/024469	8450532
4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE	11/954000	7553840
4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS AND METHODS OF THEIR USE	12/468974	7709493
METHODS OF USING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS	12/754341	7968559
4-Phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-Based Compounds and Methods of Their Use	13/162989	8772482
METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS	12/144953	8093291
METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION AND RELATED DISEASES AND DISORDERS	12/169815	7875622
METHODS OF TREATING PULMONARY HYPERTENSION	13/006592	8410121

Title / Name	Application No.	Grant No.
SOLID FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)-PYRIMIDIN-4-YL)PHENYL)PROPANOATE AND METHODS OF THEIR USE	12/237455	8193204
SOLID FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)-PYRIMIDIN-4-YL)PHENYL)PROPANOATE AND METHODS OF THEIR USE	13/486103	8653094
METHODS OF PREPARING 4-PHENYL-6-(2,2,2-TRIFLUORO-1-PHENYLETHOXY)PYRIMIDINE-BASED COMPOUNDS	13/160678	8575362
1-PHENYL-1H-PYRAZOLE-BASED COMPOUNDS	12/732311	7968729
SOLID DOSAGE FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOATE	16/688658	Pending
OLID FORMS OF (S)-2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)PYRIMIDIN-4-YL)PHENYL)PROPANOIC ACID	13/288366	8772483
AUTOMATICALLY OPERABLE SAFETY SHIELD SYSTEM FOR SYRINGES	11/740598	7500964
METHOD OF TREATING CANCER WITH TELOTRISAT OR A PRODRUG THEREOF	17/317120	Pending

CANADIAN PATENT REGISTRATIONS

Title / Name	Owner	Serial No.	Filing Date	Issue Date
COMBINATIONS OF ZICONOTIDE AND OPIOIDS FOR REDUCING PAIN	TERSERA THERAPEUTICS LLC (United States of America)	CA 2540895	2004-10-01	2016-08-02
SOLID FORMS OF (S)-ETHYL 2-AMINO-3-(4-(2-AMINO-6-((R)-1-(4-CHLORO-2-(3-METHYL-1H-PYRAZOL-1-YL)PHENYL)-2,2,2-TRIFLUOROETHOXY)-PYRIMIDIN-4-YL)PHENYL)PROPANOATE AND METHODS OF THEIR USE	TERSERA THERAPEUTICS LLC (United States of America)	CA 2700835	2008-09-25	2018-01-09
COMBINATIONS OF ZICONOTIDE AND OPIOIDS FOR REDUCING PAIN	TERSERA THERAPEUTICS LLC (United States of America)	CA 2930900	2004-10-01	2018-10-16

2. Second Lien Patent Security Agreement against JDP Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of April 4, 2023 and recorded in the United States Patent and Trademark Security Office on April 5, 2023 at Reel/Frame 063227/0713 covering the following:

REGISTERED PATENTS AND PATENT APPLICATIONS

Title / Name	Application No.	Grant No.
--------------	-----------------	-----------

NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	12/704089	8263581
NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	12/829857	8314083
NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	13/238453	8513259
NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	13/644290	9180090
NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	13/559954	9119771
NON-SEDATING ANTIHISTAMINE INJECTION FORMULATIONS AND METHODS OF USE THEREOF	13/940747	9161902
DOSING REGIMEN FOR INJECTABLE CETIRIZINE	16/594919	11253513
DOSING REGIMEN FOR INJECTABLE CETIRIZINE	16/656656	Pending

3. Second Lien Patent Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of November 26, 2024 and recorded in the United States Patent and Trademark Security Office on December 2, 2024 at Reel/Frame 069451/0158 covering the following:

ISSUED PATENTS AND PATENT APPLICATIONS

Country	Appl. Number	Filing Date	Pub. Number	Pub. Date	Patent Number	Issue Date	Status
Title: HER2/neu-specific antibodies and methods of use same							
US	12/933,885	3/25/2009	20110097323	4/28/2011	8,802,093	8/12/2014	Issued
US	14/332,239	7/15/2014	20140328836	11/6/2014	9,243,069	1/26/2016	Issued
US	14/994,892	1/13/2016	20160130360	5/12/2016	9,469,692	10/18/2016	Issued
US	15/266,421	9/15/2016	20170218083	8/3/2017	10,131,713	11/20/2018	Issued
US	16/156,382	10/10/2018	20190233539	8/1/2019	11,028,183	6/8/2021	Issued
US	17/308,356	5/5/2021	20220089773	3/24/2022	12,024,569	7/2/2024	Issued
Title: HER2/neu-Specific Antibodies And Methods Of Using Same							
US	18/394,869	12/22/2023	20240131162	4/25/2024			Pending
Title: Combination Therapy for the Treatment of Cancer							
US	15/580,969	6/9/2016	20180298100	10/18/2018	11,078,279	8/3/2021	Issued
US	17/351,724	6/18/2021	20220041725	2/10/2022			Pending
Title: Pharmaceutical Compositions of a HER2/neu Antibody and Use of the Same							
US	17/541,926	12/3/2021	20220177602	6/9/2022	11,459,399	10/4/2022	Issued
US	17/821,945	8/24/2022	20230053747	2/23/2023			Pending
Title: Identification and engineering of antibodies with variant fc regions and methods of using same							
US	10/754,922	1/9/2004	20050037000	2/17/2005	7,355,008	4/8/2008	Issued
US	12/022,762	1/30/2008	20080138344	6/12/2008	8,003,774	8/23/2011	Issued
US	12/022,772	1/30/2008	20080131435	6/5/2008	8,192,737	6/5/2012	Issued
US	13/524,652	6/15/2012	20120276094	11/1/2012	8,697,071	4/15/2014	Issued

4. Second Lien Trademark Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of April 4, 2023 and recorded in the United States Patent and Trademark Security Office on April 5, 2023 at Reel/Frame 8034/0229 covering the following:

REGISTERED TRADEMARKS

Mark Name	App. No.	App. Date	Current Owner	Reg. No.	Reg. Date
TERSER (CLASS 5)	86/900284	2/08/16	TerSera Therapeutics LLC	5242344	7/11/17
TERSER (CLASS 5)	90/667235	4/19/22	TerSera Therapeutics LLC	6704745	4/19/22
TERSER (CLASS 42)	86/900298	2/08/16	TerSera Therapeutics LLC	5807179	7/16/2019
ERGOMAR	77/942800	2/23/10	TerSera Therapeutics LLC	3859849	10/12/10
XERMELO & DESIGN	87/320213	1/31/17	TerSera Therapeutics LLC	6034081	4/14/20
XERMELO	86/013323	7/17/13	TerSera Therapeutics LLC	5200148	5/9/17
VARUBI ROLAPITANT AND DESIGN	86/593815	4/10/15	TerSera Therapeutics LLC	5335795	11/14/17
VARUBI	86/591285	4/8/15	TerSera Therapeutics LLC	4893721	1/26/16
QMIIZ AND DESIGN	88/399750	4/24/19	TerSera Therapeutics LLC	5896525	6/11/19
QMIIZ	88/091334	8/24/18	TerSera Therapeutics LLC	5777593	6/11/19
PRIALT ACCESS & SUPPORT PROGRAM AND DESIGN	87/021069	5/2/16	TerSera Therapeutics LLC	5728231	4/16/19
PRIALT	75/909746	2/4/00	TerSera Therapeutics LLC	2806847	1/20/04
CUBE DESIGN	87/320215	1/31/17	TerSera Therapeutics LLC	6034082	4/14/20


TRADEMARK APPLICATIONS

Mark Name	App. No.	App. Date	Current Owner
T	97/550026	8/16/22	TerSera Therapeutics LLC
T	97/550016	8/16/22	TerSera Therapeutics LLC

IP LICENSES



Trademark	App Date / App No.	Registration Date / Registration No.	Status
ZOLADEX	July 1, 1985 / 73545833	July 29, 1986 / 1402790	Registered
ZOLADEX	Dec. 14, 1989 / 74/010646	Nov. 27, 1990 / 1624402	Registered
SAFESYSTEM	Aug. 28, 2002 / 78/158492	Jan. 15, 2008 / 3370124	Registered

CANADIAN TRADEMARK REGISTRATIONS

Mark Name	Current Owner	App. No.	App. Date	Reg. No.	Reg. Date
XERMELO 	TerSera Therapeutics LLC	1850084	7/31/17	TMA1071513	2/3/20

TERSERA	TerSera Therapeutics LLC	1834437	4/26/17	TMA1008084	11/1/18
XERMELO	TerSera Therapeutics LLC	1680859	6/11/14	TMA1071511	2/3/20
PRIALT	TerSera Therapeutics LLC	1068845	7/28/00	TMA725302	10/3/08

CANADIAN TRADEMARK APPLICATIONS

Mark Name	Current Owner	App. No.	App. Date
	TerSera Therapeutics LLC	2203824	8/11/22
	TerSera Therapeutics LLC	2203825	8/11/22

5. Second Lien Trademark Security Agreement against JDP Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of April 4, 2023 and recorded in the United States Patent and Trademark Security Office on April 5, 2023 at Reel/Frame 8034/0210 covering the following:

REGISTERED TRADEMARKS

Mark Name	App. No.	App. Date	Current Owner	Reg. No.	Reg. Date
QUZYTIR	88/153622	10/12/18	JDP Therapeutics LLC	6034685	4/14/20

6. Second Lien Trademark Security Agreement against TerSera Therapeutics LLC, a Delaware limited liability company, in favor of Newstone Capital Partners, LLC, in its capacity as administrative agent, dated as of November 26, 2024 and recorded in the United States Patent and Trademark Security Office on December 2, 2024 at Reel/Frame 8665/0434 covering the following:

TRADEMARK REGISTRATIONS

Mark Name	App. No./App. Date	Status	Current Owner	Reg. No./ Reg. Date	Jurisdiction
MARGENZA	App 88027290 App 05-JUL-2018	Registered Intent to Use - Filed USE APPLICATION - CURRENT	MACROGENICS, INC.	Reg 6364792 Reg 25-MAY-2021	USPTO